false 0001850270 0001850270 2023-11-28 2023-11-28

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 28, 2023

 

 

PROKIDNEY CORP.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Cayman Islands   001-40560   98-1586514

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

2000 Frontis Plaza Blvd.  
Suite 250  
Winston-Salem, North Carolina     27103
(Address of Principal Executive Offices)     (Zip Code)

Registrant’s Telephone Number, Including Area Code: 336 999-7029

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Class A ordinary shares, $0.0001 par value per share   PROK   The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 28, 2023, ProKidney Corp. (“ProKidney” or the “Company”) notified Deepak Jain, Ph.D., Chief Operating Officer of the Company, of the termination of his employment without cause, effective as of the same date, following which Dr. Jain is expected to continue to serve as a consultant to the Company. The Company expects to enter into a separation agreement with Dr. Jain, the terms of which will be disclosed once available. ProKidney expresses its gratitude to Dr. Jain for his almost two decades of scientific and operating leadership to bring the Company’s Renal Autologous Cell Therapy (REACT®) product candidate from pre-clinical and early clinical development into Phase 3.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    PROKIDNEY CORP.
Date: November 30, 2023     By:  

/s/ Todd Girolamo

    Name:   Todd Girolamo
    Title:   Chief Legal Officer
v3.23.3
Document and Entity Information
Nov. 28, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001850270
Document Type 8-K
Document Period End Date Nov. 28, 2023
Entity Registrant Name PROKIDNEY CORP.
Entity Incorporation State Country Code E9
Entity File Number 001-40560
Entity Tax Identification Number 98-1586514
Entity Address, Address Line One 2000 Frontis Plaza Blvd.
Entity Address, Address Line Two Suite 250
Entity Address, City or Town Winston-Salem
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27103
City Area Code 336
Local Phone Number 999-7029
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Class A ordinary shares, $0.0001 par value per share
Trading Symbol PROK
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
ProKidney (NASDAQ:PROK)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more ProKidney Charts.
ProKidney (NASDAQ:PROK)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more ProKidney Charts.